Shots:

• The FDA’s BT designation is based on ongoing P-I/II PIVOT-02 study assessing the doublet therapy in patients with metastatic melanoma. FDA’s BT designation is to expedite the development of medicine targeting life-threatening diseases
• In Feb 2018- BMS signed a WW development and commercialization agreement with Nektar for its Bempegaldesleukin
• Nektar’s Bempegaldesleukin is a therapy targeting CD122 receptors- activating CD8+ effector T cells and NK cells and is being evaluated in P-III study in combination with Opdivo vs Opdivo in patients with 1L advanced melanoma. Opdivo is a PD-1 immune checkpoint inhibitor harnessing the body’s immune system by restoring anti-tumor response

Click here to­ read full press release/ article

Ref: BMS | Image: BMS